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Bleeding Avoidance Strategies
Consensus and Controversy
Harold L. Dauerman, MD,* Sunil V. Rao, MD,† Frederic S. Resnic, MD,§ Robert J. Applegate, MD‡
Burlington, Vermont; Durham and Winston-Salem, North Carolina; and Boston, Massachusetts
Bleeding complications after coronary intervention are associated with prolonged hospitalization, increased hos-
pital costs, patient dissatisfaction, morbidity, and 1-year mortality. Bleeding avoidance strategies is a term incor-
porating multiple modalities that aim to reduce bleeding and vascular complications after cardiovascular cathe-
terization. Recent improvements in the rates of bleeding complications after invasive cardiovascular procedures
suggest that the clinical community has successfully embraced specific strategies and improved patient care in
this area. There remains controversy regarding the efficacy, safety, and/or practicality of 3 key bleeding avoid-
ance strategies for cardiac catheterization and coronary intervention: procedural (radial artery approach, saf-
ezone arteriotomy), pharmacological (multiple agents), and technological (vascular closure devices) approaches
to improved access. In this paper, we address areas of consensus with respect to selected modalities in order to
define the role of each strategy in current practice. Furthermore, we focus on areas of controversy for selected
modalities in order to define key areas warranting cautious clinical approaches and the need for future random-
ized clinical trials in this area. (J Am Coll Cardiol 2011;58:1–10) © 2011 by the American College of Cardiol-
ogy Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.039Marso et al. (1) summarized a percutaneous coronary
intervention (PCI)-related performance measure by coining
the term bleeding avoidance strategies (BAS) in their analysis
of over 1.5 million patients undergoing PCI in contempo-
rary U.S. practice. This analysis demonstrated that BAS
incorporating vascular closure devices (VCDs) and bivaliru-
din strategies were associated with a significantly reduced
bleeding risk across a broad spectrum of patients undergoing
PCI. These findings challenge the recent American Heart
Association (AHA) scientific statement generating a Class
III/contraindication for VCDs as a method of avoiding
bleeding complications (2). This controversy is clinically
relevant because major bleeding complications are associ-
ated with significant cost, transfusions, lengthened hospi-
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(3–7). Furthermore, implementation of best practices may
improve quality of care, and guideline recommendations are
a component of this process (8). Thus, identification of
acceptable practices in preventing bleeding complications is
of paramount clinical importance.
In this article, we address this controversy by analyzing
BAS in the context of temporal trends in bleeding
complications, recognizing that changes in multiple vari-
ables may explain these trends. We categorize BAS in 3
broad themes (Fig. 1)—procedural, pharmacological, and
technological—to identify areas of consensus for clinical
practice as well as areas of controversy that warrant
further investigation.
Temporal Trends in
Bleeding and Vascular Complications
Temporal trend studies from the CathPCI Registry, North-
ern New England Cardiovascular Disease Study Group,
Mayo Clinic, and Wake Forest University demonstrate that
major bleeding complications among patients undergoing
PCI have decreased over time (9–13) (Fig. 2). Among
250,000 acute coronary syndrome (ACS) patients under-
going PCI in the CathPCI Registry, access site bleeding
complications in 2005 were 1.2% and reduced to 0.78% in
2009 (p  0.001). During this period of time, there were
significant increases in the use of at least 2 potential PCI
BAS strategies: the radial approach and use of bivalirudin
(10). Access site bleeding improvements are not confined to
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higher risk than men for bleeding
complications, yet temporal
trends in women show a similar
50% reduction in bleeding and
vascular complications during
the past decade (12).
Bleeding complications can
occur at a variety of locations.
Among patients undergoing
PCI, the most common site of
bleeding is the vascular access
site; however, in the ACS popu-
lation, in which there is a sub-
stantial proportion of patients
treated medically or with coro-
nary artery bypass surgery, the
majority of bleeding complica-
tions are not access site related
(14). Studies indicate that gastrointestinal bleeding is the
most common non-access site of hemorrhage among ACS
patients and those undergoing PCI (15,16), and is associ-
ated with significant early mortality risk (17). There are few
studies that have examined site-specific trends in bleeding,
but ACS registries have come to differing conclusions on
trends in overall major bleeding. The GRACE (Global
Registry of Acute Coronary Events) investigators have
shown a reduced frequency of major bleeding for ACS
patients between 2000 and 2007 (2.6% to 1.8%; p 0.0001)
(18). In contrast, Roe et al. (10) examined the ACTION
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Figure 1 Bleeding Avoidance Strategies Classified Into 3 Broad
Potential improvements in bleeding complications may be related to procedural, p
GPI  glycoprotein IIb/IIIa inhibitor(s).Registry–Get With the Guidelines and found that in-
hospital bleeding complications remained unchanged be-
tween 2007 and 2009 (10). In addition, among ACS
patients in the National Cardiovascular Data Registry
(NCDR) CathPCI registry, gastrointestinal bleeding in-
creased a small, but significant, amount between 2005 and
2009 (0.54 vs. 0.67%, p  0.0001).
One confounding variable occurring throughout this
discussion of bleeding trends and BAS is the variable
definition of bleeding. This variability occurs across all
registries as well as multiple different trial-based definitions
(14,19,20). Not only does this make interstudy comparisons
difficult or impossible, the utilization of the clinically most
appropriate definition of bleeding may affect conclusions
regarding relative efficacy of BAS. An example of this
debate is the inclusion of large hematoma (5 cm) in the
definition of major bleeding in some trials (21,22) or the
reliance on Thrombolysis In Myocardial Infarction major
bleeding to define clinical significance (14,20). Unlike other
areas that have accepted uniform definitions related to
important clinical endpoints (23), a unifying definition of
bleeding is still being established (24).
Despite this problem with definitions, we have registry
evidence that: 1) post-PCI access site bleeding has im-
proved; 2) this improvement is seen across a broad spectrum
of risk; and 3) trends in nonaccess site bleeding are unclear,
and there may have been a slight increase in gastrointestinal
bleeding. These temporal trend findings follow consistent
evidence in randomized clinical trials for certain BAS
techniques: bivalirudin (as compared with unfractionated
egories
cological, and technology changes occurring over the past 2 decades.Cat
harma
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fondaparinux (as compared with enoxaparin) (26), and the
radial artery approach (as compared with the femoral
approach) (27) decrease post-PCI bleeding complications
by at least 40% compared with the control strategy. For
other BAS techniques, randomized clinical trial evidence is
not definitive (13,28,29), and registry data must support or
refute the temporal trend findings. For each BAS, knowl-
edge gaps remain, and thus controversy can be identified
(Table 1). In order to better understand how each BAS may
potentially be contributing to the positive temporal trends in
Figure 2 Temporal Trends in Bleeding Complications After Perc
Each registry study shows a significant reduction in access site bleeding complica
Bleeding definitions may vary among the registries, and the time periods of compa
Selected Bleeding Avoidance Strategies: Consensus and ControverTable 1 Selected Bleeding Avoidance Strategies: Consensus a
Consensus
Pharmacology
Bivalirudin Reduction in bleeding
Fondaparinux Reduction in bleeding
Enoxaparin Predictable anticoagulation
Technology
Vascular closure devices Improved ambulation
Improved comfort
Procedural
Radial artery Reduction in bleeding
Optimized femoral access Reduction in selected bleeding complicatioPCI  percutaneous coronary intervention; UFH  unfractionated heparin.bleeding complications, the ensuing sections will analyze
areas of consensus and controversy for each approach.
Procedural Reduction in Bleeding Complications
and the Radial Artery Approach
A number of procedural developments have been imple-
mented with a goal of reducing access site–related bleeding
complications (Fig. 1). Earlier sheath removal and use of
smaller femoral artery sheaths have been associated with
reduction in bleeding complications (9,30–32). More recent
eous Coronary Intervention
ver time at each center or region analyzed.
are also different.
ntroversy
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Mechanism of mortality benefit
Benefit compared to UFH alone
Benefit during radial artery PCI
Utilization in PCI
Catheter thrombus
Intravenous, subcutaneous doses
Monitoring
Increased, decreased, or neutral bleeding complications
Increased, decreased, or neutral bleeding complications
Operator issues and learning curve
Patient suitability
Prevention of radial artery occlusion
Universal applicability and efficacy (angiography, fluoroscopy, ultrasound)utan
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cess with the goal of reducing multiple needle punctures and
non-safezone arteriotomy (puncture above the inferior epi-
gastric artery or below the common femoral artery) (28,33).
Such optimization techniques include fluoroscopic-guided
(34) or ultrasound-guided access, with superiority of the
ultrasound guidance approach demonstrated in a single
multicenter randomized trial (35). Because ultrasound-
guided access is not widely used, it is unlikely that this
particular modality can explain the recent favorable trends in
access site bleeding complications.
A procedural approach that has been consistently associ-
ated with reduced bleeding and vascular complications is
transradial cardiac catheterization and PCI (27,36,37). Both
the randomized (27,37) and observational data (36) show a
consistency in directionality of the effect of the radial
approach on bleeding. From a pathophysiological stand-
point, the underlying mechanisms related to the bleeding
reduction with transradial PCI are straightforward: the
radial artery is superficial, small in caliber, and easily
compressed. The largest observational study involved over
593,000 patients in the NCDR CathPCI Registry under-
going femoral or radial procedures (36). This study dem-
onstrated that the radial approach was associated with a 67%
reduction in bleeding and vascular complications as com-
pared with the femoral approach, without an increase in
procedural failure. This is consistent with multiple random-
ized trials that have compared transradial PCI with non-
radial access techniques (27,37,38).
As opposed to the CathPCI registry analysis, randomized
trials have shown that there may be a higher rate of
procedure failure with the radial approach, necessitating
crossover to femoral access (27,37). This discrepancy is
likely the result of selection bias inherent in observational
studies conducted in countries where there is low uptake of
the radial approach (such as in the United States) (39). The
success of transradial PCI may be dependent on operator
experience (40–42). Although a minimum number of
procedures necessary to achieve competence has not been
identified, the rates of procedure failure may plateau after
100 cases (43). It should be noted that crossover to the
femoral approach from the radial approach may be lower at
centers where the primary approach is transradial; moreover,
crossover from femoral to radial access also occurs but is
rarely captured in registry data.
Access site bleeding is associated with significant discom-
fort and patient dissatisfaction. In this context, patients
appear to prefer the radial to the femoral approach (44). In
addition, reduction in vascular and bleeding complications is
associated with cost savings from the hospital perspective
(38,41,44,45). Given these data, wider adoption of the
radial approach to improve the safety of PCI is a reasonable
objective. Of note, improvement of traditional efficacy
measures (such as death and myocardial infarction) with the
radial approach could not be demonstrated in a recently
published randomized trial (RIVAL [An International lRandomized Trial of Trans-radial Versus Trans-femoral
Percutaneous Coronary Intervention (PCI) Access Site
Approach in Patients With Unstable Angina or Myocardial
Infarction Managed With an Invasive Strategy]) (37,38).
Other issues related to the radial approach that require
further investigation include radiation exposure and radial
artery occlusion (46). The latter appears to occur with a
frequency between 0.6% and 12% (47–49). Radial artery
occlusion is often asymptomatic due to the presence of
collateral flow in the hand in most patients (50); however, it
is not known whether transradial PCI impacts the suitability
of the radial artery as a conduit for coronary artery bypass
grafting. Radial artery occlusion can be minimized by the
use of anticoagulation during transradial procedures, smaller
catheters, and “patent hemostasis” after sheath removal
(47,49).
Despite the relatively large effects of transradial PCI on
bleeding complications, large registry studies show that
transradial PCI accounts for 5% of U.S. PCI procedures
(36); it is much more common outside the United States
(39). Therefore, although the data for decreased bleeding
complications with the radial approach are consistent, the
low adoption rate of the radial approach in the United
States makes it unlikely to be a main explanation for the
decrease in bleeding complications in the United States.
Given this low adoption rate for radial-mediated BAS, it is
worthwhile to consider alternative (pharmacological and
mechanical) BAS strategies.
Pharmacological Reduction
in Bleeding Complications
Similar to the radial artery approach, pharmacological de-
velopments have already passed the test of appropriate
randomized clinical trials. First, the use of unfractionated
heparin with and without GPI agents has changed over the
past decade. Between 1991 and 1997, 3 trials of the use of
abciximab demonstrated progressive improvements in
bleeding rates (30,51). Comparing the control arms of each
study, which received heparin without a GPI, the overall
bleeding rates decreased by 79% (8.2% in the EPIC [Eval-
uation of c7E3 for the Prevention of Ischemic Complica-
tions] trial vs. 1.7% in the EPISTENT [Evaluation of
Platelet IIb/IIIa Inhibitor for Stenting] trial, p  0.001).
his improvement was attributed to reductions in the dose
f heparin and the lower target activated clotting time levels
n the later trials (30). The active treatment arm patients
eceiving abciximab also experienced a 90% reduction in
ascular bleeding rates from 20.2% to 2.1% (30). Similarly,
he ISAR (Intracoronary Stenting and Antithrombotic
egimen) group has recently demonstrated an association
etween lower heparin dosing (100 U/kg) and a reduction in
leeding complications after PCI in a comparison with a
istorical control group (140 U/kg) (52).
More predictable anticoagulation may be achieved withow molecular weight heparins. Enoxaparin has been exten-
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reduction in bleeding complications with enoxaparin versus
unfractionated heparin (53,54). Other studies have either
shown a neutral effect on bleeding with enoxaparin (55), or
an increased risk of bleeding with this agent compared with
unfractionated heparin (56,57). These findings may be
explained by differences in patient populations, sheath
management, drug dosing, and route of administration (i.e.,
intravenous versus subcutaneous) (32,58). Of note, enoxa-
parin use has increased outside the United States in recent
temporal trends studies (2000 to 2007) of acute coronary
syndromes; during that period of time, bleeding has de-
creased (18). On the other hand, enoxaparin use has
decreased in U.S. practice, and bleeding has also decreased
(10). These data point to the complexity of understanding
the role of any single pharmacological, technological, or
procedural approach in accounting for recent favorable
trends in bleeding.
Other randomized clinical trial evidence is more consis-
tent: the indirect factor Xa inhibitor fondaparinux signifi-
cantly reduces bleeding risk as compared with enoxaparin
with similar rates of ischemic complications at 9 days
(59,60). These benefits may be especially prominent in
patients with renal dysfunction (61). Limited adoption of
fondaparinux for PCI patients (due to concerns about
catheter-related thrombus [59]) make this agent unlikely to
be a major component of recent favorable bleeding trends.
Whether recent randomized trial data on efficacy of adjunc-
tive low-dose unfractionated heparin to prevent catheter
thrombus formation impacts utilization of this agent re-
mains to be determined (62).
Bivalirudin, a direct thrombin inhibitor, is associated
with a 40% to 50% reduction in bleeding complications
when compared with heparin-based strategies (25,63,64).
Of note, bivalirudin does not protect against bleeding
complications when used in conjunction with GPI agents
(as compared with unfractionated heparin with GPI) (25).
The bleeding reduction with bivalirudin compared with
unfractionated heparin/GPI regimens remains significant
even in the presence of lower doses of heparin: in the
PROTECT–TIMI 30 (Randomized Trial to Evaluate the
Relative PROTECTion against Post-PCI Microvascular
Dysfunction and Post-PCI Ischemia among Anti-Platelet
and Anti-Thrombotic Agents–Thrombolysis In Myocardial
Infarction 30), a heparin dose of 50 U/kg was tested in
conjunction with GPI and bivalirudin still maintained a
significant reduction in bleeding complications (65). An
even more creative way to limit the impact of unfractionated
heparin dosing on GPI-related bleeding effects is to reverse
heparin with protamine after PCI completion: comparison
of bivalirudin against this ultimate low-dose heparin/GPI
strategy, though, still reveals a significant reduction in
bleeding complications with bivalirudin (66,67). More re-
cent studies have explored the use of shorter duration or
intracoronary-bolus-only administration of GPI agents to
limit bleeding side effects: whether these approaches reducebleeding compared with bivalirudin alone has not been
examined (68,69). Lastly, the bleeding reduction seen with
bivalirudin is not confined to selected clinical trial popula-
tions; large-scale registry studies have similarly demon-
strated significant associations between reduced bleeding
complications and bivalirudin utilization (1,12).
Many areas of controversy remain regarding implemen-
tation of bivalirudin in clinical practice: for example, up-
stream use of unfractionated heparin (with switching),
dosing of clopidogrel, and mortality reduction in STEMI
(ST-segment elevation myocardial infarction) trials remain
areas of ongoing discussion and subgroup analysis (70–73).
Even more controversial is the comparison of bivalirudin to
unfractionated heparin alone (i.e., without routine use of
GPI). The ISAR-REACT 3 (Intracoronary Stenting and
Antithrombotic Regimen: Rapid Early Action for Coronary
Treatment 3) trial compared bivalirudin against heparin
alone (140 U/kg) and found that bivalirudin reduced bleed-
ing complications; unlike the bivalirudin versus heparin/
GPI trials (63,64), the net efficacy of a bivalirudin strategy
compared with heparin alone in this stable/unstable angina
PCI population could not be demonstrated (74–76). How-
ever, the reduction in bleeding complications with bivaliru-
din compared with either heparin alone or heparin/GPI is
consistent. Whether or not bivalirudin is superior to a
lower-dose heparin strategy (or heparin reversed with prota-
mine) has not been determined. Changes in pharmacology
are a plausible component of positive bleeding temporal
trends: for example, utilization of bivalirudin for PCI has
increased absolutely an approximate 20% in U.S. practice
between 2005 and 2009 (p  0.001) with concomitant
decreased use of heparin and GPI regimens (10).
Mechanical Reduction in
Bleeding Complications: VCDs
A recent AHA Scientific Statement has issued a Class III
(Level of Evidence: B) recommendation/contraindication
related to VCDs for the purpose of reducing vascular
complications (2). Manual compression of the femoral
artery access site has been the gold standard in obtaining
hemostasis at the access site for the past several decades.
After almost 60 years of percutaneous arterial access, hemo-
stasis by manual compression remains unchanged; the
exception is the introduction of topical hemostasis patches
that have not demonstrated a reduction in major bleeding
complications in trials or registries (77,78).
In the early 1990s, VCDs were introduced. Koreny et al.
(79) evaluated clinical outcomes from randomized clinical
trials of VCDs versus manual compression. They identified
30 studies with almost 4,000 patients and demonstrated less
time to ambulation and shorter length of hospitalization
with VCDs as compared with manual compression. The
safety analysis was neutral: neither improvement nor reduc-
tion in the rates of vascular complications with VCDs
compared with manual compression could be demonstrated.
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but this was based upon a sensitivity analysis of only 2 of the
30 trials in which intention to treat could be identified.
Nikolsky et al. (80), in a broader meta-analysis that included
both randomized trials and registries, identified 30 studies
with 37,066 patients comparing clinical outcomes after
VCDs versus manual compression. These authors observed
an overall higher risk of vascular complication with VCDs
compared with manual compression when all studies were
combined. But, the adverse risk of VCDs was shown to be
a result of a significantly higher rate of vascular complica-
tions particularly with the VasoSeal device (Datascope,
Montvale, New Jersey) compared with manual compression.
Contrary to these two studies, Vaitkus (81) and the U.S.
Federal Drug Administration (82) came to a different
conclusion: examining 2001 data from the NCDR CathPCI
Registry, the Federal Drug Administration observed
findings similar to that of Vaitkus: the use of VCDs was
associated with a significant reduction in vascular com-
plications as compared with manual compression, and
VasoSeal was a notable exception to those positive trends
(Table 2).
Several factors are relevant in examining the use of the
older data to determine the current safety of VCDs. First,
VCDs may have improved over time (83), especially with
the removal of the VasoSeal product (82). Second, there is
a learning curve with the use of VCDs (84,85); it is possible
that better patient selection and knowledge of device use
itself has resulted in lower rates of vascular complications.
Unfortunately, the potential benefit of these incremental
changes has not been absolutely proven: the equivocal and
conflicting results did not spur the VCD industry to settle
the question finally and definitely with a single, large
randomized clinical trial.
However, since the conflicting meta-analyses of 2004,
there have been at least 5 large (10,000 patients),
broadly inclusive observational and multicenter registries
evaluating the safety of VCDs (Table 2). Arora et al. (86)
looked at rates of vascular complications in 12,937
patients from 2002 to 2005. They observed an almost
50% propensity-adjusted reduction in rates of vascular
Studies With 10,000 or More Patients: VCD Versus MCTable 2 Studies With 10,000 or More Patients: VCD Versus M
First Author
(Ref. #) Year Published N Study Type
Nikolsky et al. (80) 2004 36,066 Trial and registry met
Tavris et al. (90) 2004 166,680 National registry (NCD
Tavris et al. (82) 2005 13,878 National registry (NCD
Arora et al. (86) 2007 12,937 Single-center registry
Ahmed et al. (12) 2007 13,563 Multicenter registry
Applegate et al. (11) 2008 35,016 Single-center registry
Sanborn et al. (87) 2009 11,621 ACUITY post-hoc
Marso et al. (1) 2010 1,522,935 National registry (NCDACUITY Acute Catheterization and Urgent Intervention Triage strategY trial; CI confidence interval; MC
odds ratio; VC  vascular closure; VCD  vascular closure device.complications associated with VCD utilization. Ahmed
et al. (12) examined the rates of vascular complications in
patients undergoing PCI from the Northern New Eng-
land Cardiovascular Disease Study Group from 2002 to
2007. They observed a 28% decrease in the risk-adjusted
rates of vascular complications in over 13,563 women
with VCDs compared with manual compression. Apple-
gate et al. (11) evaluated rates of vascular complications
in 35,016 patients over a 10-year study period, ending in
2007: VCD use was an independent factor associated
with lower rates of vascular complications. Sanborn et al.
performed a post-hoc analysis of the ACUITY (Acute
Catheterization and Urgent Intervention Triage strat-
egY) trial (87): in 11,621 patients, there was a significant
22% risk-adjusted decrease in the rates of vascular com-
plications with the use of VCDs compared with manual
compression. Finally, Marso et al. (1) reviewed the data
from the American College of Cardiology NCDR from
2004 to 2008. Over 1.5 million patients were included in
the study, with a significantly lower rate of vascular
complications with VCD use compared with manual
compression across a broad spectrum of risk.
An appropriately powered randomized trial is needed
prior to definitive conclusions (i.e., Class I or Class III
recommendations). The etiologies of favorable temporal
trends is complex and not easily attributable to a single
device or intervention: in the Mayo Clinic study of
17,901 consecutive patients between 1994 and 2005,
major femoral vascular complications were reduced by
58% (from 8.4% to 3.5%, p  0.001); notably, the use of
VCDs comprised 5% of patients during the study
period (9). Although the Northern New England group
also demonstrated a 50% reduction in bleeding compli-
cations over time, Northern New England operators
utilized VCDs in 43% of patients (12). The potential
benefit of VCDs (early ambulation, comfort [13,88])
coupled with the inconsistent data regarding safety of
VCDs (80,82) do not meet the burden of proof of harm;
clinicians should be left in the appropriate gray area of
Class II recommendations for this technology.
Endpoint
Complication Rates
p ValueVCD MC
sis Hematoma OR: 1.34 95% CI: 1.01–1.79 0.05
Any VC 1.10% 1.70% 0.001
Any VC OR: 0.99 95% CI: 0.77–1.28 NS
Any VC 2.40% 4.90% 0.01
Bleeding/VC OR: 0.72 95% CI: 0.59–0.89 0.02
Any VC 1.60% 2.10% 0.03
Access site bleeding 2.50% 3.30% 0.01
Periprocedural bleeding OR: 0.77 95% CI: 0.73–0.80 0.05C
a-analy
R)
R)
R)manual compression; NCDR National Cardiovascular Data Registry; NS not significant; OR
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Systematic improvements in bleeding complications may
require broad initiatives to address patient selection and
BAS implementation. One approach is the application of a
Bleeding Risk Score to individualize patient approaches
with tailoring of therapies according to patient risk
(21,74,89,90). Therapeutic strategies based upon risk strat-
ification for bleeding complications, though, may be limited
by the overlap between ischemic risk factors and bleeding
risk factors (74,89). As another example, the relative benefit
of VCDs as compared with manual compression may
depend upon the adequacy of femoral artery access and
selection of appropriate patients (28,29,34,91). The conse-
quences of VCD closure failure are not small: Bangalore
reported a VCD failure rate of 2.3% in 9,853 consecutive
patients, demonstrating that VCD failure was associated with
a 4.8-fold increased risk of vascular complication compared
with successful VCD deployment in a propensity-matched
analysis (92). Thus, systematic attempts to optimize femoral
access (including potentially fluoroscopy-guided access, se-
lected ultrasound-guided access, and routine femoral angiog-
raphy [28,34,35]) in order to determine which VCDs are
appropriate in selected situations warrants further study.
Even if appropriately deployed BAS conclusively reduce
bleeding, can the incremental costs of bivalirudin/
fondaparinux (compared with heparins) and VCDs (as
compared with manual compression) be justified? The
significant economic costs of bleeding and vascular compli-
cations following PCI can provide additional incentive for
increased focus on bleeding reduction strategies. A detailed
analysis of the incremental costs of complications based on
administrative data from 335,477 Medicare beneficiaries
who underwent PCI in 2002, demonstrated an incremental
cost of $6,377 and an increased length of stay of 2.8 days for
patients suffering a vascular complication (93).
Exploring the ACUITY randomized clinical trial data,
Pinto et al. (45) determined that the use of bivalirudin was
associated with a net cost savings, ostensibly through the
reduction of bleeding complications. Specifically, minor
bleeding events were associated with an attributable cost of
$2,282, whereas major bleeding episodes were associated
with an increased attributable cost of $8,658 (45). Similarly,
a detailed attributable cost analysis of specific vascular and
bleeding complications demonstrated significant incremen-
tal additional costs of hematoma ($1,399, 95% confidence
interval [CI]: $700 to $6,955), clinically significant bleeding
($5,440, 95% CI: $2,250 to $10,226), and pseudoaneurysm
formation ($6,357, 95% CI: $4,900 to $10,408) (5). Given
the significant costs associated with bleeding and vascular
complications following PCI, BAS may ultimately be cost-
effective investments of health care.
As noted previously, the radial access strategy has been
found to be associated with a significant reduction of access
site bleeding complications as compared with femoral accessprocedures. Balancing the costs and clinical advantages of
VCDs, bivalirudin, and radial access is complex. Although
radial access obviates the need for VCD use, many radial
access interventionalists recommend the use of specially
designed hydrophilic sheaths, wires, and radial access site
hemostasis devices to help improve the success and patient
comfort associated with the radial artery approach. The
incremental costs for these specialized radial access devices
range from $55 to $75 per procedure above the costs of
traditional femoral access equipment. Although there are
potential advantages for bivalirudin to reduce nonaccess site
bleeding in radial artery access procedures as compared with
a strategy of heparin use, lesser absolute reductions in overall
bleeding complications are likely to result in lesser cost
effectiveness as compared with the demonstrated cost ad-
vantages in femoral access (45,94).
Consensus, Controversy,
and Practice Recommendations
BAS have emerged as an evolving and important part of
cost-effective, high-quality clinical practice. Consensus
points from randomized clinical trials and registries are
robust:
• Access site bleeding complication rates are less frequent
now than 10 years ago in the setting of multiple phar-
macological, technological, and procedural advances.
• Bivalirudin, fondaparinux, and lower-dose unfraction-
ated heparin are associated with a significant reduction
in bleeding complications compared with regimens
incorporating higher-dose unfractionated heparin
and/or GPI.
• The radial approach reduces access site bleeding com-
pared with the femoral approach, but the slow adop-
tion in the United States makes it unlikely to fully
explain the falling rates of bleeding complications.
• The radial artery approach and vascular closure devices
allow earlier ambulation and improve patient comfort
compared with femoral access/manual compression
strategy.
• Bleeding complications are associated with increased
hospital costs, lengthened hospitalization, and mortality.
On the other hand, controversy remains regarding other
aspects of BAS:
• Early meta-analyses and registry studies demonstrate
harm, benefit, and neutrality of VCDs compared with
manual compression, depending upon analysis of over-
all results versus sensitivity analyses. In contrast, 5
recent large (10,000 patients) registries suggest a
benefit for VCDs compared with manual compression.
Based on these registries, a large randomized trial is
warranted to prove the concept that VCDs decrease
complications.
• Are BAS-related pharmacological agents necessary in
the setting of the radial approach? Can U.S barriers to
radial adoption be overcome?
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1-year death, the mechanism (i.e., cessation of guide-
line recommended antiplatelet therapy [95]) remains
speculative.
Conclusions
The coining of the term bleeding avoidance strategies sum-
marizes a broad multimodality approach to quality improve-
ment for invasive cardiovascular procedures. The trends in
this area are positive, indicating that clinicians are moving in
the right direction. Randomized clinical trial data are robust
in many areas and allow for considerable consensus. On the
other hand, controversy is both expected and warranted in
areas where adequately sized clinical trials have not yet been
performed. In such areas, clinical judgment, patient selec-
tion, and cautious utilization are consistent with other gray
areas of current practice.
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